Tingle M D, Mahmud R, Maggs J L, Pirmohamed M, Park B K
Department of Pharmacology and Therapeutics, The University of Liverpool, Ashton Street Medical School, Liverpool, L69 3GE, United Kingdom.
J Pharmacol Exp Ther. 1997 Nov;283(2):817-23.
The metabolism and toxicity of dapsone was compared in vitro and in vivo in rat, mouse and man. Metabolism was assessed by high-pressure liquid chromatography-mass spectrometry and methemoglobin formation has been used as a toxic endpoint. The greatest toxicity in vitro was seen in microsomes prepared from male Wistar rats (36.6 +/- 1.5% methemoglobin), although toxicity was also seen in microsomes from the female rat (8.2 +/- 1.3%), male CD1 (4.2 +/- 1.6%) and human (10. 9 +/- 1.1%). The rank order of toxicity agreed with the formation of the hydroxylamine metabolite in vitro. All microsomes were also capable of catalyzing the reverse reaction, i.e., reduction of the hydroxylamine to dapsone. However, in vivo administration of dapsone resulted in significant (P < 0.05) methemoglobinemia only in male rats and humans. This species difference in the susceptibility to dapsone toxicity could not be attributed solely to the sensitivity of the target erythrocytes, because the order of sensitivity to dapsone hydroxylamine was human > mouse > rat. Analysis of bile and urine revealed the formation of dapsone hydroxylamine and its glucuronide in male rats and humans, but not in female rats or mice. This species difference in the metabolism and toxicity of dapsone has important implications in the safety evaluation of related compounds for man.
对氨苯砜在大鼠、小鼠和人体中的代谢及毒性进行了体外和体内比较。通过高压液相色谱 - 质谱法评估代谢情况,并将高铁血红蛋白形成用作毒性终点。体外毒性最大的是雄性Wistar大鼠制备的微粒体(高铁血红蛋白含量为36.6±1.5%),不过雌性大鼠(8.2±1.3%)、雄性CD1小鼠(4.2±1.6%)和人体(10.9±1.1%)的微粒体也有一定毒性。毒性的排序与体外羟胺代谢物的形成情况一致。所有微粒体也都能够催化逆反应,即将羟胺还原为氨苯砜。然而,体内给予氨苯砜仅在雄性大鼠和人体中导致显著(P<0.05)的高铁血红蛋白血症。氨苯砜毒性易感性的这种物种差异不能仅归因于靶红细胞的敏感性,因为对氨苯砜羟胺的敏感性顺序是人体>小鼠>大鼠。胆汁和尿液分析显示,雄性大鼠和人体中形成了氨苯砜羟胺及其葡糖醛酸苷,但雌性大鼠或小鼠中未形成。氨苯砜代谢和毒性的这种物种差异对相关化合物用于人体的安全性评估具有重要意义。